Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

fedratinib

- PMLiVE

Celgene bid to push Revlimid beyond myeloma blocked again

Cancer treatment fails phase III trial in lymphoma

Strategic symbionts

Strategic alliances are becoming more interesting and more important 

- PMLiVE

Neurodegenerative disorders market set to reach $45bn by 2022

But shake-up expected from flurry of new approvals and patent expirations

Celgene to apply machine learning to market access

Signs agreement for rights to GNS Healthcare's simulation platform

- PMLiVE

FDA green light for Pfizer’s eczema drug

Blockbuster-hopeful Eucrisa expected to launch early next year at $580 per 60mg tube

- PMLiVE

Celgene scoops Socially Responsible Initiative prize at PMEA 2016

Lauded for 'inspirational' initiative that tackled real need in developing countries

- PMLiVE

Takeda gets EU green light for oral myeloma drug

Ninlaro first oral proteasome inhibitor to be registered in Europe

- PMLiVE

NICE U-turn sees Celgene’s Imnovid backed for multiple myeloma

New data and a discount swayed the cost-effectiveness body

- PMLiVE

Bayer wins Company of the Year at PMEA 2016

Sees off strong competition from AbbVie, Celgene and Novartis

- PMLiVE

NICE set to knock-back Amgen’s myeloma treatment Kyprolis

Cites uncertainty in clinical and cost-effectiveness analyses

Celgene building

Celgene engages IBM Watson for patient safety work

Aims to improve its pharmacovigilance methods with a new cloud-based platform

Celgene plans real-world study using Apple’s ResearchKit

Will develop an iPhone app to assess burden of chronic anaemia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links